NASDAQ:ADAP

Adaptimmune Therapeutics - ADAP Price Target & Analyst Ratings

$1.06

0.00 (0.00%)

(As of 03/30/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.04
▼
$1.10
50-Day Range: $1.06
▼
$1.87
52-Week Range: $1.01
▼
$2.65

Volume: 250,503 shs
Average Volume: 561,074 shs
Market Capitalization: $163.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.12

Institutional Ownership

Adaptimmune Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$6.12
477.36% Upside

High Prediction	$10.00
Average Prediction	$6.12
Low Prediction	$3.00

Type	Current 3/31/22 to 3/31/23	1 Month Ago 3/1/22 to 3/1/23	3 Months Ago 12/31/21 to 12/31/22	1 Year Ago 3/31/21 to 3/31/22
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	3 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$6.12	$6.00	$5.00	$7.60
Predicted Upside	477.36% Upside	210.88% Upside	134.01% Upside	54.28% Upside

Get Adaptimmune Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

ADAP Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ADAP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Adaptimmune Therapeutics Stock vs. The Competition

Type	Adaptimmune Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.64	2.47
Consensus Rating	Moderate Buy	Buy	Hold
Predicted Upside	477.36% Upside	2,011.77% Upside	93.71% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/24/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$3.60	+230.27%
3/6/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$10.00	+666.28%
1/3/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$5.00	+242.46%
11/14/2022	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight	$1.50 ➝ $3.00	+19.52%
11/9/2022	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$9.00	+332.69%
3/15/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform	$7.00 ➝ $3.00	+64.83%

9/13/2021	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Soumit Roy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$15.00	+155.97%
5/28/2021	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underweight	$4.00	-20.79%
9/9/2020	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$42.00 ➝ $42.00	+426.32%
8/12/2020	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight
4/27/2020	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$8.00 ➝ $5.00	+44.93%

(Data available from 3/31/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

ADAP Price Target - Frequently Asked Questions

What is Adaptimmune Therapeutics's consensus rating and price target?: According to the issued ratings of 5 analysts in the last year, the consensus rating for Adaptimmune Therapeutics stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for ADAP. The average twelve-month price prediction for Adaptimmune Therapeutics is $6.12 with a high price target of $10.00 and a low price target of $3.00. Learn more on ADAP's analyst rating history.
Do Wall Street analysts like Adaptimmune Therapeutics more than its competitors?: Analysts like Adaptimmune Therapeutics more than other Medical companies. The consensus rating for Adaptimmune Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ADAP compares to other companies.
Is Adaptimmune Therapeutics being upgraded by Wall Street analysts?: Over the previous 90 days, Adaptimmune Therapeutics's stock had 1 upgrade by analysts.

Does Adaptimmune Therapeutics's stock price have much upside?: According to analysts, Adaptimmune Therapeutics's stock has a predicted upside of 262.34% based on their 12-month price targets.
What analysts cover Adaptimmune Therapeutics?: Adaptimmune Therapeutics has been rated by Bryan, Garnier & Co, EF Hutton Acquisition Co. I, and Guggenheim in the past 90 days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

This page (NASDAQ:ADAP) was last updated on 3/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial